Here the antibody (or its single-chain variable fragments) serves as the tumor-targeting ligand for recognizing the CD19 molecules on cell surface, and brings anticancer drugs or T lymphocytes to tumor cells [7, 8]. The gene discussed is CD19; the disease is neoplasm.